Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00646230 · ClinicalTrials.gov registry record · Phase 1

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

A Phase 1 study of Neuroblastoma, sponsored by Nant Operations Center.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target
13
Study locations

NCT00646230 is a Phase 1 study of Neuroblastoma that has completed, run by Nant Operations Center. The registered enrollment target is 17 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00646230, a Phase 1 study of Neuroblastoma, has completed, sponsored by Nant Operations Center.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target
13
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma.

Conditions Studied

Neuroblastoma

Interventions

  • OTHER pharmacological study
  • OTHER high performance liquid chromatography
  • DRUG fenretinide

Study Locations (13)

California

  • Childrens Hospital Los Angeles - Los Angeles
  • Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Texas

  • Cook Children's Medical Center - Fort Worth - Fort Worth
  • Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital - Houston

Georgia

  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus - Atlanta

Illinois

  • University of Chicago Comer Children's Hospital - Chicago

Massachusetts

  • Children's Hospital Boston - Boston

Michigan

  • C.S. Mott Children's Hospital at University of Michigan Medical Center - Ann Arbor

New York

  • Morgan Stanley Children's Hospital of New York-Presbyterian - New York

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2006-12
Est. Completion 2012-03
Phase Phase 1

Sponsor

Nant Operations Center

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00646230

The ClinicalTrials.gov registry entry for NCT00646230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (93% lower). The listed sponsor is Nant Operations Center, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which pharmacological study is the first listed.

NCT00646230 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Texas, Georgia.

Frequently Asked Questions

What is clinical trial NCT00646230 about?

NCT00646230 is a clinical study titled "N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma". RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young pa...

What is the current status of trial NCT00646230?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2006-12. Estimated completion is 2012-03.

What conditions does trial NCT00646230 study?

This clinical trial studies the following conditions: Neuroblastoma.

What interventions are being tested in trial NCT00646230?

The interventions under investigation include: pharmacological study (OTHER), high performance liquid chromatography (OTHER), fenretinide (DRUG).

Who is sponsoring clinical trial NCT00646230?

This trial is sponsored by Nant Operations Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00646230 being conducted?

This trial has 13 study locations across California, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuroblastoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.